Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. XNCR
XNCR logo

XNCR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Xencor Inc (XNCR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
15.670
1 Day change
5.24%
52 Week Range
18.690
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Xencor Inc (XNCR) is not a strong buy for a beginner, long-term investor at this time. The stock lacks significant positive catalysts, has neutral trading sentiment, and analysts expect the stock to remain range-bound in the near term. Additionally, there are no strong trading signals or recent financial data to support a compelling entry point.

Technical Analysis

The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 67.586, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 12.212, with resistance at 13.022 and support at 11.402.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
0
Buy
11

Positive Catalysts

  • NULL identified. No recent news or significant insider/hedge fund activity.

Neutral/Negative Catalysts

  • Analysts have downgraded the stock to Neutral, citing 2026 as a year of execution with no clear catalysts for significant growth. The stock is expected to remain range-bound in the near term.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have a Neutral rating on the stock. JPMorgan recently raised the price target to $14 from $13 but maintains a cautious outlook, citing the need for clarity on execution and pipeline development.

Wall Street analysts forecast XNCR stock price to rise
5 Analyst Rating
Wall Street analysts forecast XNCR stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.890
sliders
Low
20
Averages
26.25
High
30
Current: 14.890
sliders
Low
20
Averages
26.25
High
30
Truist
Buy
downgrade
$29 -> $27
AI Analysis
2026-07-07
New
Reason
Truist
Price Target
$29 -> $27
AI Analysis
2026-07-07
New
downgrade
Buy
Reason
Truist lowered the firm's price target on Xencor to $27 from $29 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage, the analyst tells investors in a research note. Truist adds that it sees a robust catalyst calendar, supported by sector optimism and deal activity, as drivers for the recent momentum across the sector.
JPMorgan
Neutral
maintain
$13 -> $14
2026-05-11
Reason
JPMorgan
Price Target
$13 -> $14
2026-05-11
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Xencor to $14 from $13 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for XNCR
Unlock Now

People Also Watch